A Phase 3 interventional study of Benralizumab in Severe Uncontrolled Asthma, sponsored by AstraZeneca. Completed at 15 sites in 2 countries. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2023-05-18.
Sponsored by AstraZeneca · Phase 3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 34th largest by enrollment, is one of 5 that started in 2019, is one of 20 in phase 3, and was the 31st registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 6 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 202nd largest by enrollment of the 248 interventional ones that give a count, is one of 24 that started in 2019, is one of 121 in phase 3, and was the 264th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the PK, PD and long-term safety of Benralizumab administered subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma. Up to an additional 3 Japanese patients aged 12 to 14 years will be enrolled to meet local regulatory requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply:
Exclusion Criteria:
Patients are eligible to be included in the study only if all of the inclusion criteria and none of the exclusion criteria apply:
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, immunological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Below 35 kilos
Drug: Benralizumab
Greater than/equal to 35 kilos
Drug: Benralizumab
Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
Clearance of Benralizumab
Blood samples were collected to determine the clearance of benralizumab. This was an empirical Bayesian estimate (EBE) derived posthoc using population PK analysis.
Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab
Blood samples were collected to determine the AUC0-28 of benralizumab and it was calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Pre-dose on Days 0, 28 and post-dose on Days 1, 7, 14
Maximum Observed Serum Concentration (Cmax) of Benralizumab
Blood samples were collected to determine Cmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Terminal Phase Elimination Half-Life (t1/2) of Benralizumab
Blood samples were collected to determine the t1/2 of benralizumab and it was calculated as natural logarithm of 2 \[ln(2)\]/terminal rate constant (λZ). This was an EBE derived posthoc using population PK analysis.
Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab
Blood samples were collected to determine the tmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Trough Concentration of Benralizumab at Week 16 (Ctrough16)
Blood samples were collected to determine the trough concentration at Week 16, the lowest concentration reached by benralizumab before the next dose was administered. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Pre-dose on Day 112
Change From Baseline in Peripheral Blood Eosinophil Count up to Week 48
Blood samples were collected for determination of eosinophil count levels and were assessed in a central laboratory. Baseline is the last non-missing measurement prior to the first dose of study treatment.
Time frame: Baseline (Day 0) and at Weeks 4, 8, 12, 16, 24 and 48
Body Weight-Adjusted Clearance of Benralizumab
Blood samples were collected to determine the clearance of benralizumab. This was an EBE derived posthoc using population PK analysis.
Time frame: Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit
Number of Participants With Anti-Drug Antibodies (ADA) Response to Benralizumab
Blood samples were analyzed for the presence of ADAs for benralizumab. ADA prevalence: ADA positive (+ve) at any time point including baseline and/or post baseline. Treatment induced ADA+ve: ADA negative (-ve) at baseline and post-baseline ADA+ve. Treatment-boosted ADA+ve: baseline +ve ADA titer that was boosted by \>4-fold or higher-level following study drug administration. Treatment-emergent ADA+ve: either treatment-induced ADA+ve or treatment-boosted ADA+ve. Persistently +ve ADA: having at least 2 post-baseline ADA+ve assessments with at least 16 weeks (112 days) between the first and last +ve assessments, or an ADA+ve result at the last available assessment. Transiently +ve ADA: having at least 1 post-baseline ADA+ve assessment(s) and not persistently ADA+ve. Neutralizing antibodies (nAb) prevalence: nAb+ve at baseline and/or post-baseline. Treatment-induced nAb+ve (nAb incidence): nAb-ve at baseline (or ADA-ve at baseline) and nAb+ve at any post-baseline visit.
Time frame: Pre-dose at Baseline (Day 0), Weeks 8, 16 and 24 and post-dose at Week 48; and at early discontinuation or withdrawal visit
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) up to Week 48
The FEV1 was defined as the volume of air exhaled from the lungs in the first second of a forced expiration and was measured by spirometry. Baseline is the last non-missing measurement with acceptable quality prior to the first dose of study treatment.
Time frame: Baseline (Day 0) and at Weeks 16 and 48
Change From Baseline in Interviewer-Administered Asthma Control Questionnaire (ACQ-IA) Score up to Week 48
The ACQ-IA is a 6-item assessment comprised of 6 patient-reported items. Participants were asked to record their experience with 5 symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, and wheezing) and use of short-acting beta-2 agonist (SABA) over the previous week using a 7-point scale (0 = no impairment; and 6 = maximum impairment). The ACQ-IA score was calculated by the mean of the 7 equally weighted items. The score ranged from 0 (well controlled) to 6 (extremely poorly controlled). Higher scores indicated poor asthma control. Baseline is the last non-missing measurement prior to the first dose of study treatment.
Time frame: Baseline (Day 0), at Weeks 16 and 48; and at early discontinuation or withdrawal visit
Number of Responders in Interviewer-Administered Patient Global Impression of Change (PGIC)-IA and Clinician Global Impression of Change (CGIC) Questionnaires
The PGIC-IA and CGIC instruments were used for an overall evaluation of response to treatment, conducted separately by the Investigator and by the participant (administered by trained individuals to help the child understand the question and response options), using a 7-point scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse. The Investigator (clinician) and the participant were asked to rate the degree of change in the overall asthma status compared to the start of study treatment visit. Participants were defined as responders based on categorized responses for PGIC-IA and CGIC. Responder status categories included Improved=Very much improved, Much improved, Minimally improved, Much improved=Much improved, Very much improved, Very much improved=Very much improved. CGIC = PGIC-IA indicates agreement between CGIC and PGIC-IA assessments of response to treatment at the same visit.
Time frame: At Weeks 16 and 48; and at early discontinuation or withdrawal visit
This Phase III, open-label, parallel group study was conducted in pediatric participants with severe eosinophilic asthma at 17 investigational sites in the United States and Japan between 21 Nov 2019 and 12 Sep 2022.
| Milestone | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 |
Blood samples were collected to determine the clearance of benralizumab. This was an empirical Bayesian estimate (EBE) derived posthoc using population PK analysis.
| liter (L) per day | All Participants |
|---|---|
| Clearance of Benralizumab | 0.156 ± 0.0598 |
Blood samples were collected to determine the AUC0-28 of benralizumab and it was calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.
| nanogram*day per milliliter (ng*day/mL) | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab | 36918.01 ± 24.61 | 75593.37 ± 39.96 | 36918.01 ± 24.61 | 73670.51 ± 38.86 |
Blood samples were collected to determine Cmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.
| ng/mL | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of Benralizumab | 1901.18 ± 28.42 | 3118.69 ± 47.35 | 1901.18 ± 28.42 | 3090.85 ± 43.66 |
Blood samples were collected to determine the t1/2 of benralizumab and it was calculated as natural logarithm of 2 \[ln(2)\]/terminal rate constant (λZ). This was an EBE derived posthoc using population PK analysis.
| day | All Participants |
|---|---|
| Terminal Phase Elimination Half-Life (t1/2) of Benralizumab | 14.4 (6.94 to 23.4) |
Blood samples were collected to determine the tmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.
| day | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab | 6.91 (0.93 to 14.95) | 7.26 (1.10 to 14.01) | 6.91 (0.93 to 14.95) | 7.94 (1.10 to 14.01) |
Blood samples were collected to determine the trough concentration at Week 16, the lowest concentration reached by benralizumab before the next dose was administered. The PK parameters were estimated using non-compartmental analysis method.
| ng/mL | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| Trough Concentration of Benralizumab at Week 16 (Ctrough16) | 142.42 ± 256.34 | 339.35 ± 409.24 | 142.42 ± 256.34 | 340.46 ± 363.69 |
Blood samples were collected for determination of eosinophil count levels and were assessed in a central laboratory. Baseline is the last non-missing measurement prior to the first dose of study treatment.
| cells/microliters | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| Week 4 | -447.3 ± 283.76 | -436.9 ± 408.28 | -447.3 ± 283.76 | -455.3 ± 385.58 |
| Week 8 | -445.3 ± 276.20 | -453.8 ± 396.03 | -445.3 ± 276.20 | -470.7 ± 374.25 |
| Week 12 | -443.3 ± 286.85 | -455.8 ± 419.32 | -443.3 ± 286.85 | -472.9 ± 393.49 |
| Week 16 | -446.7 ± 279.12 | -402.7 ± 384.61 | -446.7 ± 279.12 | -430.0 ± 378.68 |
| Week 24 | -354.2 ± 323.99 | -436.9 ± 405.90 | -354.2 ± 323.99 | -457.9 ± 397.77 |
| Week 48 | -434.0 ± 286.15 | -453.8 ± 392.78 | -434.0 ± 286.15 | -474.3 ± 385.04 |
Blood samples were collected to determine the clearance of benralizumab. This was an EBE derived posthoc using population PK analysis.
| L/day/kilogram | All Participants |
|---|---|
| Body Weight-Adjusted Clearance of Benralizumab | 0.00408 ± 0.000764 |
Blood samples were analyzed for the presence of ADAs for benralizumab. ADA prevalence: ADA positive (+ve) at any time point including baseline and/or post baseline. Treatment induced ADA+ve: ADA negative (-ve) at baseline and post-baseline ADA+ve. Treatment-boosted ADA+ve: baseline +ve ADA titer that was boosted by \>4-fold or higher-level following study drug administration. Treatment-emergent ADA+ve: either treatment-induced ADA+ve or treatment-boosted ADA+ve. Persistently +ve ADA: having at least 2 post-baseline ADA+ve assessments with at least 16 weeks (112 days) between the first and last +ve assessments, or an ADA+ve result at the last available assessment. Transiently +ve ADA: having at least 1 post-baseline ADA+ve assessment(s) and not persistently ADA+ve. Neutralizing antibodies (nAb) prevalence: nAb+ve at baseline and/or post-baseline. Treatment-induced nAb+ve (nAb incidence): nAb-ve at baseline (or ADA-ve at baseline) and nAb+ve at any post-baseline visit.
| Participants | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| ADA prevalence | 3 | 1 | 3 | 1 |
| Treatment-emergent ADA+ve | 3 | 1 | 3 | 1 |
| Post-baseline ADA+ve | 3 | 1 | 3 | 1 |
| Baseline and at least 1 post-baseline ADA+ve | 0 | 0 | 0 | 0 |
| Only baseline ADA+ve | 0 | 0 | 0 | 0 |
| Persistently ADA+ve | 1 | 0 | 1 | 0 |
| Transiently ADA+ve | 2 | 1 | 2 | 1 |
| nAb prevalence | 3 | 1 | 3 | 1 |
| nAb incidence | 3 | 1 | 3 | 1 |
The FEV1 was defined as the volume of air exhaled from the lungs in the first second of a forced expiration and was measured by spirometry. Baseline is the last non-missing measurement with acceptable quality prior to the first dose of study treatment.
| liters | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| Week 16 | -0.001 ± 0.2434 | -0.119 ± 0.2435 | -0.001 ± 0.2434 | -0.165 ± 0.2609 |
| Week 48 | 0.003 ± 0.3412 | 0.425 ± 0.4395 | 0.003 ± 0.3412 | 0.428 ± 0.4209 |
The ACQ-IA is a 6-item assessment comprised of 6 patient-reported items. Participants were asked to record their experience with 5 symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, and wheezing) and use of short-acting beta-2 agonist (SABA) over the previous week using a 7-point scale (0 = no impairment; and 6 = maximum impairment). The ACQ-IA score was calculated by the mean of the 7 equally weighted items. The score ranged from 0 (well controlled) to 6 (extremely poorly controlled). Higher scores indicated poor asthma control. Baseline is the last non-missing measurement prior to the first dose of study treatment.
| scores on a scale | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| Week 16 | -0.62 ± 0.890 | -1.18 ± 1.717 | -0.62 ± 0.890 | -1.06 ± 1.696 |
| Week 48 | -0.56 ± 1.252 | -1.36 ± 1.369 | -0.56 ± 1.252 | -1.31 ± 1.324 |
The PGIC-IA and CGIC instruments were used for an overall evaluation of response to treatment, conducted separately by the Investigator and by the participant (administered by trained individuals to help the child understand the question and response options), using a 7-point scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse. The Investigator (clinician) and the participant were asked to rate the degree of change in the overall asthma status compared to the start of study treatment visit. Participants were defined as responders based on categorized responses for PGIC-IA and CGIC. Responder status categories included Improved=Very much improved, Much improved, Minimally improved, Much improved=Much improved, Very much improved, Very much improved=Very much improved. CGIC = PGIC-IA indicates agreement between CGIC and PGIC-IA assessments of response to treatment at the same visit.
| Participants | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| PGIC-IA, Week 16, improved | 13 | 12 | 13 | 13 |
| PGIC-IA, Week 16, much improved | 10 | 10 | 10 | 11 |
| PGIC-IA, Week 16, very much improved | 4 | 8 | 4 | 9 |
| PGIC-IA, Week 48, improved | 13 | 12 | 13 | 13 |
| PGIC-IA, Week 48, much improved | 9 | 10 | 9 | 11 |
| PGIC-IA, Week 48, very much improved | 9 | 9 | 9 | 10 |
| CGIC, Week 16, improved | 13 | 11 | 13 | 12 |
| CGIC, Week 16, much improved | 8 | 9 | 8 | 9 |
| CGIC, Week 16, very much improved | 3 | 5 | 3 | 5 |
| CGIC, Week 48, improved | 15 | 13 | 15 | 14 |
| CGIC, Week 48, much improved | 8 | 11 | 8 | 12 |
| CGIC, Week 48, very much improved | 5 | 6 | 5 | 6 |
| CGIC = PGIC-IA, Week 16, improved | 10 | 6 | 10 | 6 |
| CGIC = PGIC-IA, Week 16, much improved | 7 | 5 | 7 | 5 |
| CGIC = PGIC-IA, Week 16, very much improved | 3 | 4 | 3 | 4 |
| CGIC = PGIC-IA, Week 48, improved | 9 | 8 | 9 | 8 |
| CGIC = PGIC-IA, Week 48, much improved | 5 | 7 | 5 | 7 |
| CGIC = PGIC-IA, Week 48, very much improved | 5 | 6 | 5 | 6 |
Collected over Treatment-emergent adverse events were collected from the start of study drug administration (Day 1) until end of follow-up, approximately up to Week 53. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab Dose 1, Aged 6-11 Years | 0/15 (0%) | 1/15 (6.7%) | 13/15 (86.7%) |
| Benralizumab Dose 2, Aged 6-11 Years | 0/13 (0%) | 2/13 (15.4%) | 9/13 (69.2%) |
| Benralizumab Dose 1, Aged 6-14 Years | 0/15 (0%) | 1/15 (6.7%) | 13/15 (86.7%) |
| Benralizumab Dose 2, Aged 6-14 Years | 0/15 (0%) | 4/15 (26.7%) | 11/15 (73.3%) |
| Event | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/15 | 2/13 | 1/15 | 4/15 |
| Somatic symptom disorderPsychiatric disorders | 0/15 | 0/13 | 0/15 | 1/15 |
| Event | Benralizumab Dose 1, Aged 6-11 Years | Benralizumab Dose 2, Aged 6-11 Years | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/15 | 1/13 | 4/15 | 2/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/15 | 3/13 | 0/15 | 3/15 |
| PyrexiaGeneral disorders | 3/15 | 1/13 | 3/15 | 1/15 |
| COVID-19Infections and infestations | 1/15 | 2/13 | 1/15 | 2/15 |
| Viral upper respiratory tract infectionInfections and infestations | 2/15 | 2/13 | 2/15 | 2/15 |
| VomitingGastrointestinal disorders | 2/15 | 0/13 | 2/15 | 0/15 |
| PneumoniaInfections and infestations | 0/15 | 1/13 | 0/15 | 2/15 |
| SinusitisInfections and infestations | 2/15 | 0/13 | 2/15 | 0/15 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/15 | 0/13 | 2/15 | 0/15 |
| HeadacheNervous system disorders | 2/15 | 1/13 | 2/15 | 1/15 |
The Safety Analysis set consisted of all participants who received at least 1 dose of benralizumab.
| Age, Continuous(years) | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years | Total |
|---|---|---|---|
| Mean | 8.3 ± 2.02 | 9.8 ± 1.93 | 9.0 ± 2.09 |
| Sex: Female, Male(Participants) | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years | Total |
|---|---|---|---|
| Female | 4 | 7 | 11 |
| Male | 11 | 8 | 19 |
| Race/Ethnicity, Customized(Participants) | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years | Total |
|---|---|---|---|
| White | 4 | 4 | 8 |
| Black or African American | 3 | 5 | 8 |
| Asian | 8 | 3 | 11 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Other | 0 | 3 | 3 |
| Race/Ethnicity, Customized(Participants) | Benralizumab Dose 1, Aged 6-14 Years | Benralizumab Dose 2, Aged 6-14 Years | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 6 |
| Not Hispanic or Latino | 14 | 10 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2019 to primary completion in Sep 2022, 33 months.
Results were first posted in May 2023, 8 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 33 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab